Search Results - "CHINOL, Marco"

Refine Results
  1. 1

    State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging by Carollo, Angela, Papi, Stefano, Grana, Chiara M, Mansi, Luigi, Chinol, Marco

    Published in Current radiopharmaceuticals (01-01-2019)
    “…Neuroendocrine Tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to grow slowly and are often diagnosed when…”
    Get more information
    Journal Article
  2. 2

    Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience by Carollo, Angela, Papi, Stefano, Chinol, Marco

    Published in Current radiopharmaceuticals (01-01-2016)
    “…Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive…”
    Get more information
    Journal Article
  3. 3

    PEPTIDE BASED TARGETED RADIONUCLIDE THERAPIES; SCIENCE BEHIND THE SUCCESS by Al Rowaily, Mohammed H, Dondi, Daniele, Chinol, Marco, Munir, Iqbal, AlAsbahi, Muaadh

    Published in Journal of cancer & allied specialties (31-12-2016)
    “…The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide therapies have been in use since 1945. In…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Yttrium-labelled peptides for therapy of NET by Bodei, Lisa, Cremonesi, Marta, Grana, Chiara M., Chinol, Marco, Baio, Silvia M., Severi, Stefano, Paganelli, Giovanni

    “…Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting…”
    Get full text
    Journal Article
  9. 9
  10. 10

    A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions by Caviglioli, Gabriele, Chinol, Marco, Baldassari, Sara, Garaboldi, Lucia, Zuccari, Guendalina, Petretto, Andrea, Drava, Giuliana, Sinico, Chiara, Paganelli, Giovanni

    Published in Scientific reports (04-04-2019)
    “…This paper describes a new nuclear imaging agent, 2-(4-isothiocyanatobenzyl)−1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid of human albumin (HAC),…”
    Get full text
    Journal Article
  11. 11

    Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs by Kwekkeboom, Dik J, Mueller-Brand, Jan, Paganelli, Giovanni, Anthony, Lowell B, Pauwels, Stanislas, Kvols, Larry K, O'Dorisio, Thomas M, Valkema, Roelf, Bodei, Lisa, Chinol, Marco, Maecke, Helmut R, Krenning, Eric P

    Published in The Journal of nuclear medicine (1978) (01-01-2005)
    “…A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group by Chinol, Marco, Bodei, Lisa, Cremonesi, Marta, Paganelli, Giovanni

    Published in Seminars in nuclear medicine (01-04-2002)
    “…High concentrations of subtype 2 somatostatin tumor receptors (sst(2)) are expressed in numerous tumors, enabling primary and metastatic masses to be localized…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Yttrium-labelled peptides for therapy of NETtherapy by Bodei, Lisa, Cremonesi, Marta, Grana, Chiara M, Chinol, Marco, Baio, Silvia M, Severi, Stefano, Paganelli, Giovanni

    “…Issue Title: Radiolabelled Peptides for Diagnosis and Therapy Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a…”
    Get full text
    Journal Article
  17. 17

    Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety by Cremonesi, Marta, Ferrari, Mahila, Paganelli, Giovanni, Rossi, Annalisa, Chinol, Marco, Bartolomei, Mirco, Prisco, Gennaro, Tosi, Giampiero

    “…The widespread interest in (90)Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Production and quality control of [90Y]DOTATOC for treatment of metastatic neuroendocrine tumors: results of 85 syntheses by Biasiotto, Giorgio, Bertagna, Francesco, Zanella, Isabella, Biasiotto, Ugo, Savelli, Giordano, Caimi, Luigi, Bettinsoli, Giovanni, Giubbini, Raffaele, Chinol, Marco

    Published in Nuclear medicine communications (01-03-2013)
    “…The aim of this paper was to describe the optimized labeling protocol and quality control measures used in the production of [Y]DOTATOC, starting from three…”
    Get full text
    Journal Article
  20. 20

    Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT) by Urbano, Nicoletta, Papi, Stefano, Ginanneschi, Mauro, De Santis, Rita, Pace, Silvia, Lindstedt, Ragnar, Ferrari, Liliana, Choi, Sunju, Paganelli, Giovanni, Chinol, Marco

    “…A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided…”
    Get full text
    Journal Article